Please assess the completion status of the following clinical trial:

Trial Title: Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with indications for AmB treatment~Exclusion Criteria:~* Patients with acute kidney injury~* Hyperkalemia ≥5.2~* Hypersensibility to spironolactone~* HIV infection~* Pregnant women~* Solid organ transplant~* Hemodynamic instability~* CKDEPI ≤30ml/min/1.73m3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone 200mg (Type: EXPERIMENTAL): Spironolactone 100 mg twice a day orally
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice a day orally
- Spironolactone 100mg (Type: EXPERIMENTAL): Spironolactone 100mg once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).